Journals / İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi / 2013 / Cilt: 3 - Sayı: 2

When should transient myeloproliferative disorder of the newborn with Down syndrome be treated? Case report

Down sendromlu yenidoğanın geçici myeloproliferatif hastalığını ne zaman tedavi edelim? Olgu sunumu

Pages
147–150
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We present a TMD case of newborn with Down syndrome and aimed to emphasize the importance of early diagnosis and therapy of these patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Transient Myeloproliferative Disorder (TMD), is an important hematological disorder which is seen in newborns with Down syndrome.
📊
Key Findings & Data:It is often self-limiting and spontane- ous remissions occur within 3 months.
💡
Conclusion & Impact:We present a TMD case of newborn with Down syndrome and aimed to emphasize the importance of early diagnosis and therapy of these patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Transient Myeloproliferative Disorder (TMD), is an important hematological disorder which is seen in newborns with Down syndrome. It is often self-limiting and spontane- ous remissions occur within 3 months. Leukocytosis, thrombocytopenia, anemia, hepatosplenomegaly, the presence of cutaneous nodules and blasts in the peripheral blood are characteristic findings. We present a TMD case of newborn with Down syndrome and aimed to emphasize the importance of early diagnosis and therapy of these patients.

Özet

Down sendromlu yenidoğanlarda görülen önemli bir hematolojik sorun, çoğu zaman kendi kendini sınırlayan ve sıklıkla 3 ay içinde spontan remisyonla sonlanan “Geçici Myeloproliferatif Bozukluk” (TMD) olarak adlandırılan durumdur. TMD’de lökosi- toz, trombositopeni, anemi, hepatosplenomegali, kutanoz noduller ve periferik kanda blastların varlığı karakteristik bulgulardır. Biz down sendromlu geçici myeloprolife- ratif hastalık tanısı alan yenidoğan olgumuzu sunduk. Bu hastaların erken dönemde tanı alması ve tedavilerinin başlamasının önemini vurgulamak istedik.

🔖

Cite This Article

GÜL, Ö., GÖKSÜGÜR, Y., DAVUTOĞLU, M., GARİPARDIÇ, M. (2013). When should transient myeloproliferative disorder of the newborn with Down syndrome be treated? Case report. İzmir Dr. Behçet Uz Çocuk Hastanesi Dergisi, Cilt: 3 - Sayı: 2, 147–150. https://ajindex.com/articles/213766

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Down JL. Observations on an ethnic classification of idiots. London Hosp Clin Lect Rep 1866. Ment Retard 1995
  2. PMid:7707939 2. Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J. Myelodysplasia and acute megakaryoblastic leukemia in Downís syndrome. Leuk Res 1994
  3. http://dx.doi.org/10.1016/0145-2126(94)90111-2 3. Reyes ZS, Bashir W, Pathare A. Transient Myeloproliferative Disorder and Down syndrome. Sultan Qaboos Univ Med J 2012
  4. PMid:23275848 PMCid:PMC3524001 4. Hitzler JK, Zipursky A. Origins of leukemia in children with down syndrome. Nat Rev Canver 2005
  5. Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW, et al. Children’s Oncology Group (COG). A pros- pective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood 2006
  6. http://dx.doi.org/10.1182/blood-2005-06-2448 PMid:16469874 6. Canpolat Cengiz. Down sendromu ve lösemi. Pediatrik Hematoloji 2011:641-50. 7. Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol 1993
  7. 15(4):392-9. PMid:8214361 8. Alan S. Gamis, 1 Todd A, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Childrenís Oncology Group Study A2971. Blood 2011
  8. http://dx.doi.org/10.1182/blood-2011-04-350017 PMid:21849481 PMCid:PMC3245202 9. Solky BA, Yang FC, Xu X, Levins P. Transient myeloprolife- rative disorder causing a vesiculopustular eruption in a pheno typically normal neonate. Pediatr Dermatol 2004
  9. 21(5):551- 4. http://dx.doi.org/10.1111/j.0736-8046.2004.21505.x PMid:15461760 10. Alford KA, Reinhardt K, Garnett C, et al. International Myeloid Leukemia-Down Syndrome Study Group. Analysis of GATA1 mutations in Down syndrome transient myelopro- liferative disorder and myeloid leukemia. Blood 2011, 25
  10. http://dx.doi.org/10.1182/blood-2011-03-342774 PMid:21715302 11. Grundy RG, Martinez A, Kompski H, et al. Spontaneous remission of congenital leukemia: a case for conservative treatment. J Pediatr Hematol Oncol 2000
  11. http://dx.doi.org/10.1097/00043426-200005000-00011 PMid:10864057 12. Hirabayashi K, Shiohara M, Takahashi D, et al. Retrospective analysis of risk factors for development of liver dysfunction in transient leukemia of Down syndrome. Leuk Lymphoma 2011
  12. 52(8):1523-7. http://dx.doi.or